Skip to main content
    I

    Immix Biopharma Inc (IMMX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $7.48
    -0.36 (-4.59%)

    Market Cap: $657.09M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Immix Biopharma Inc (IMMX) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Immix Biopharma (IMMX) to earn -$0.72 per share in the fiscal year ending Dec 31, 2026. Of 7 analysts, 7 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 2 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 7 ratings average 1.57, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.

    RatingAnalystsShare
    Strong Buy342.9%
    Buy457.1%
    Hold00.0%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    7

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a larger loss.

    Fiscal year ending Dec 31, 2026
    -$0.72
    EPS consensus
    Fiscal year ending Dec 31, 2027
    -$0.95
    EPS consensus, revenue $27.86M
    Next report
    Mar 23, 2027
    Estimated

    EPS range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.72-$0.80 to -$0.518N/AN/A5
    Dec 31, 2027-$0.95-$1.45 to -$0.208$27.86MN/A6

    Quarterly Estimates

    Quarter endingEPS consensusEPS rangeEPS analysts
    Dec 31, 2026-$0.21-$0.25 to -$0.189

    Estimate Revisions

    Across the 2 periods below, the last 30 days brought 3 upward and 4 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202621
    Fiscal year ending Dec 31, 202713

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$0.71.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$0.72-$0.72-$0.71-$0.75-$0.71N/A
    Fiscal year ending Dec 31, 2027-$0.95-$0.95-$0.85-$0.91-$0.84N/A

    Frequently Asked Questions About IMMX

    What is the IMMX stock forecast?

    Consensus analyst estimates put Immix Biopharma's EPS at -$0.72 for the fiscal year ending Dec 31, 2026. The consensus rating from 7 analysts is Buy.

    How do analysts rate IMMX stock?

    Of 7 analysts covering Immix Biopharma, 3 rate it Strong Buy, 4 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from IMMX next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.72, with estimates from -$0.80 to -$0.51 from 8 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.95, with estimates from -$1.45 to -$0.20 from 8 analysts.

    What revenue do analysts expect from Immix Biopharma next year?

    For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $27.86M.

    How many analysts cover IMMX?

    7 analysts rate Immix Biopharma stock, and 8 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.